Current and historical daily PE Ratio for Inotiv Inc (
FRA:BS50
) from 1997 to Sep 22 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Inotiv stock (FRA:BS50) PE ratio as of Sep 22 2024 is 0.
More Details
Inotiv Inc (FRA:BS50) PE Ratio (TTM) Chart
Inotiv Inc (FRA:BS50) PE Ratio (TTM) Historical Data
View and export this data going back to 1997. Start your Free Trial
Total 1265
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Inotiv PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-09-22 | At Loss | 2024-07-22 | At Loss |
| 2024-09-20 | At Loss | 2024-07-19 | At Loss |
| 2024-09-19 | At Loss | 2024-07-18 | At Loss |
| 2024-09-18 | At Loss | 2024-07-17 | At Loss |
| 2024-09-17 | At Loss | 2024-07-16 | At Loss |
| 2024-09-16 | At Loss | 2024-07-15 | At Loss |
| 2024-09-13 | At Loss | 2024-07-12 | At Loss |
| 2024-09-12 | At Loss | 2024-07-11 | At Loss |
| 2024-09-11 | At Loss | 2024-07-10 | At Loss |
| 2024-09-10 | At Loss | 2024-07-09 | At Loss |
| 2024-09-09 | At Loss | 2024-07-08 | At Loss |
| 2024-09-06 | At Loss | 2024-07-05 | At Loss |
| 2024-09-05 | At Loss | 2024-07-04 | At Loss |
| 2024-09-04 | At Loss | 2024-07-03 | At Loss |
| 2024-09-03 | At Loss | 2024-07-02 | At Loss |
| 2024-09-02 | At Loss | 2024-07-01 | At Loss |
| 2024-08-30 | At Loss | 2024-06-28 | At Loss |
| 2024-08-29 | At Loss | 2024-06-27 | At Loss |
| 2024-08-28 | At Loss | 2024-06-26 | At Loss |
| 2024-08-27 | At Loss | 2024-06-25 | At Loss |
| 2024-08-26 | At Loss | 2024-06-24 | At Loss |
| 2024-08-23 | At Loss | 2024-06-21 | At Loss |
| 2024-08-22 | At Loss | 2024-06-20 | At Loss |
| 2024-08-21 | At Loss | 2024-06-19 | At Loss |
| 2024-08-20 | At Loss | 2024-06-18 | At Loss |
| 2024-08-19 | At Loss | 2024-06-17 | At Loss |
| 2024-08-16 | At Loss | 2024-06-14 | At Loss |
| 2024-08-15 | At Loss | 2024-06-13 | At Loss |
| 2024-08-14 | At Loss | 2024-06-12 | At Loss |
| 2024-08-13 | At Loss | 2024-06-11 | At Loss |
| 2024-08-12 | At Loss | 2024-06-10 | At Loss |
| 2024-08-09 | At Loss | 2024-06-07 | At Loss |
| 2024-08-08 | At Loss | 2024-06-06 | At Loss |
| 2024-08-07 | At Loss | 2024-06-05 | At Loss |
| 2024-08-06 | At Loss | 2024-06-04 | At Loss |
| 2024-08-05 | At Loss | 2024-06-03 | At Loss |
| 2024-08-02 | At Loss | 2024-05-31 | At Loss |
| 2024-08-01 | At Loss | 2024-05-30 | At Loss |
| 2024-07-31 | At Loss | 2024-05-29 | At Loss |
| 2024-07-30 | At Loss | 2024-05-28 | At Loss |
| 2024-07-29 | At Loss | 2024-05-27 | At Loss |
| 2024-07-26 | At Loss | 2024-05-24 | At Loss |
| 2024-07-25 | At Loss | 2024-05-23 | At Loss |
| 2024-07-24 | At Loss | 2024-05-22 | At Loss |
| 2024-07-23 | At Loss | 2024-05-21 | At Loss |
Inotiv Inc (FRA:BS50) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Inotiv Inc
NAICS : 325412
SIC : 2834
ISIN : US45783Q1004
Description
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers